Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 3/2010

01.09.2010 | Original Paper

Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-κB-mediated induction of XIAP, cIAP2, BCL-XL and survivin

verfasst von: Majid Momeny, Majid Zakidizaji, Reza Ghasemi, Ahmad R. Dehpour, Maryam Rahimi_Balaei, Yassan Abdolazimi, Ardeshir Ghavamzadeh, Kamran Alimoghaddam, Seyed H. Ghaffari

Erschienen in: Medical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the present study is to evaluate the effects of arsenic trioxide (ATO) on human acute promyelocytic leukemia NB-4 cells. Microculture tetrazolium test, bromodeoxyuridine (BrdU) cell proliferation assay, caspase 3 activity assay, cell-based nuclear factor kappa B (NF-κB) phosphorylation measurement by ELISA and real-time RT-PCR were employed to appraise the effects of ATO on metabolic activity, DNA synthesis, induction of programmed cell death and NF-κB activation. The suppressive effects of ATO on metabolic potential, cell proliferation and NF-κB activation were associated with induction of apoptosis in NB-4 cells. In addition, an expressive enhancement in mRNA levels of p73, cyclin-dependent kinase inhibitor 1A (p21), tumor protein 53-induced nuclear protein 1 (TP53INP1), WNK lysine deficient protein kinase 2 (WNK2) and lipocalin 2 coupled with a significant reduction in transcriptional levels of NF-κB inhibitor beta (IKK2), Nemo, BCL2-like 1 (BCL-XL), inhibitor of apoptosis protein 1 (cIAP2), X-linked inhibitor of apoptosis protein (XIAP), survivin, Bcl-2, TIP60, ataxia telangiectasia (ATM), SHP-2 and sirtuin (SIRT1) were observed. Altogether, these issues show for the first time that ATO treatment could trammel cell growth and proliferation as well as induces apoptosis in NB-4 cells through induction of transcriptional levels of p73, TP53INP1, WNK2, lipocalin 2 as well as suppression of NF-κB-mediated induction of BCL-XL, cIAP2, XIAP and survivin. Furthermore, the inductionary effects of ATO on transcriptional stimulation of p73 might be through cramping the NF-κB module (through suppression of p65 phosphorylation as well as transcriptional hindering of IKK2, ATM and Nemo) along with diminishing the mRNA expression of TIP60, SHP-2 and SIRT1.
Literatur
1.
Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12–22.PubMed
2.
Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 2002;295:1079–82.CrossRefPubMed
3.
Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther. 2009;8:160–70.CrossRefPubMed
4.
Yu J, Qian H, Li Y, Wang Y, Zhang X, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol. 2007;106:400–6.CrossRefPubMed
5.
Park M, Lee J, Kwak H, Park C, Lee H, et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kB and reactive oxygen species. J Cell Biochem. 2005;95:955–69.CrossRefPubMed
6.
Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investig New Drugs. 2002;20:327–30.CrossRef
7.
Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood. 2008;111:5152–62.CrossRefPubMed
8.
Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103–8.PubMed
9.
Li H, He J, Ju P, Zhong X, Liu J. Studies on the mechanism of arsenic trioxide-induced apoptosis in HepG2 human hepatocellular carcinoma cells. Chin J Clin Oncol. 2008;5:22–5.CrossRef
10.
Zhou L, Chan JY, Wang J, Fung K. Anti-proliferation of MDA-MB-231 human breast tumor cells by arsenic trioxide via induction of apoptosis. Res J Med Sci. 2008;2:236–43.
11.
Cheung WM, Chu PW, Kwong YL. Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells. Cancer Lett. 2007;246:122–8.CrossRefPubMed
12.
Venepalli NK, Altman JK, Tallman MS. Evolving role of arsenic trioxide in acute promyelocytic leukemia. Clin Leuk. 2006;1:36–40.CrossRef
13.
Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893–903.PubMed
14.
Wei L, Lai K, Chen C, Cheng C, Huang Y, et al. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB. Oncogene. 2005;24:390–8.CrossRefPubMed
15.
Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001;91:173–9.CrossRefPubMed
16.
Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, et al. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol. 1998;102:1055–60.CrossRefPubMed
17.
Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Investig. 2001;108:1541–7.PubMed
18.
Yih LH, Lee T. Arsenite induces p53 accumulation through an ATM dependent pathway in human fibroblasts. Cancer Res. 2000;60:6346–52.PubMed
19.
Kroemer G, de The′ H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst. 1999;91:743–5.CrossRefPubMed
20.
Shen Z, Shen J, Cai W, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med. 2000;5:155–8.PubMed
21.
22.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.CrossRefPubMed
23.
Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2:605–15.CrossRefPubMed
24.
Melino G, Bernassola F, Ranalli M, Yee K, Xing Zong W, et al. p73 induces apoptosis via puma transactivation and bax mitochondrial translocation. J Biol Chem. 2004;279:8076–83.CrossRefPubMed
25.
Yang A, McKeon F. P63 and P73:P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 1997;1:199–207.CrossRef
26.
Tomasini R, Seux M, Nowak J, Bontemps C, Carrier A, et al. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene. 2005;24:8093–104.PubMed
27.
Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 2002;9:237–45.CrossRefPubMed
28.
Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol. 2007;210:161–6.CrossRefPubMed
29.
Ruhul Amin A, Thakur VS, Paul RK, Feng GS, Qu C, et al. SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. PNAS. 2007;104:5419–24.CrossRef
30.
Kim JW, Song PI, Jeong MH, An JH, Lee SY, et al. TIP60 represses transcriptional activity of p73beta via an MDM2-bridged ternary complex. J Biol Chem. 2008;283:20077–86.CrossRefPubMed
31.
Baud V, Karin M. Is NFκB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8:33–40.CrossRefPubMed
32.
Deveraux Q, Reed J. IAP family proteins-suppressors of apoptosis. Gene Dev. 1999;13:239–52.CrossRefPubMed
33.
Karin M, Cao Y, Greten F, Li Z. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossRefPubMed
34.
Bonizzi G, Karin M. The two NF-kappa activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280–8.CrossRefPubMed
35.
Kikuchi H, Ozaki T, Furuya K, Hanamoto T, Nakanishi M, et al. NF-κB regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway. Oncogene. 2006;25:7608–17.CrossRefPubMed
36.
Moniz S, Veríssimo F, Matos P, Brazão R, Silva E, et al. Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. Oncogene. 2007;26:6071–81.CrossRefPubMed
37.
Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 2006;280:13641–7.CrossRef
38.
Grosjean-Raillard J, Tailler M, Ades L, Perfettini JL, Fabre C, et al. ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 2009;28:1099–109.CrossRefPubMed
39.
Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–6.CrossRefPubMed
40.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–60.PubMed
41.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101–8.CrossRefPubMed
42.
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2005;17:131–4.CrossRefPubMed
43.
Alimoghaddam K, Shariftabrizi A, Tavangar M, Sanaat Z, Rostami S, et al. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leuk Lymphoma. 2006;47:81–8.CrossRefPubMed
44.
Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A. Real-time PCR analysis of PML-RAR in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol. 2006;17:1553–9.CrossRefPubMed
45.
Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.CrossRefPubMed
46.
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345–53.PubMed
47.
Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149–63.CrossRefPubMed
48.
Kim H, Rafiuddin-Shah M, Tu H, Jeffers JR, Zambetti GP, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006;8:1348–58.CrossRefPubMed
49.
Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, et al. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403–10.CrossRefPubMed
50.
Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, et al. Trichostatin A up-regulates p73 and induces bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther. 2008;7:1410–9.CrossRefPubMed
51.
Song X, Sheppard HM, Norman AW, Liu X. Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line. J Biol Chem. 1999;274:1677–82.CrossRefPubMed
52.
Tomasini R, Azizi Samir A, Carrier A, Isnardon D, Cecchinelli B, et al. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem. 2003;278:37722–9.CrossRefPubMed
53.
Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17–26.CrossRefPubMed
54.
Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297–309.CrossRefPubMed
55.
Tong Z, Wu X, Kehrer JP. Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem J. 2003;372:203–10.CrossRefPubMed
56.
Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006;24:841–51.CrossRefPubMed
57.
Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 2006;24:827–39.CrossRefPubMed
58.
Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKK gamma by SUMO-1 and ubiquitin mediates NF-kappa B activation by genotoxic stress. Cell. 2003;115:565–76.CrossRefPubMed
Metadaten
Titel
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-κB-mediated induction of XIAP, cIAP2, BCL-XL and survivin
verfasst von
Majid Momeny
Majid Zakidizaji
Reza Ghasemi
Ahmad R. Dehpour
Maryam Rahimi_Balaei
Yassan Abdolazimi
Ardeshir Ghavamzadeh
Kamran Alimoghaddam
Seyed H. Ghaffari
Publikationsdatum
01.09.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9294-9

Weitere Artikel der Ausgabe 3/2010

Medical Oncology 3/2010 Zur Ausgabe

Original Paper

Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis

Original Paper

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature

Original Paper

Quality of life and depression among metastatic breast cancer patients

Original Paper

Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway

Original Paper

Primary gastrointestinal non-Hodgkin’s lymphoma: clinicopathological and prognostic analysis

Original Paper

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise